Literature DB >> 7244563

Subacute bacterial endocarditis due to Actinobacillus actinomycetemcomitans.

T Hofstad, A Stallemo.   

Abstract

A case of infective endocarditis in a 59-year-old female caused by Actinobacillus actinomycetemcomitans is reported. The organism was recovered from 9 blood cultures. Despite treatment with penicillin and gentamicin the illness led to destruction of the aortic valve.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7244563     DOI： 10.1080/00365548.1981.11690372

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  6 in total

1.  A novel factor isolated from Actinobacillus actinomycetemcomitans stimulates mouse B cells and human peripheral blood mononuclear cells.

Authors:  S J Jeong; S T Yee; W S Jo; S H Yu; S H Lee; Y J Lim; Y H Yoo; J M Kim; J D Lee; M H Jeong
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  Introns in the cytolethal distending toxin gene of Actinobacillus actinomycetemcomitans.

Authors:  Kai Soo Tan; Grace Ong; Keang Peng Song
Journal:  J Bacteriol       Date:  2005-01       Impact factor: 3.490

3.  Immune suppression induced by Actinobacillus actinomycetemcomitans: effects on immunoglobulin production by human B cells.

Authors:  B J Shenker; L A Vitale; D A Welham
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  Endocarditis caused by Actinobacillus actinomycetemcomitans.

Authors:  Y Siegman-Igra; D Schwartz; O Ophir; N Konforti
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

5.  Endocarditis caused by Actinobacillus actinomycetemcomitans.

Authors:  S H Schack; P W Smith; R G Penn; J M Rapoport
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

6.  Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c+CD8+ T cells in renal cell carcinoma.

Authors:  Seong-A Ju; Sang-Min Park; Yeonsoo Joe; Hun Taeg Chung; Won G An; Byung-Sam Kim
Journal:  Oncol Lett       Date:  2021-12-06       Impact factor: 2.967
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.